ArticleBMC gastroenterology2025
Macroscopic growth patterns and their molecular implications in gastric carcinoma: toward risk stratification via borrmann classification.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Borrmann type IV gastric cancer exhibits distinct clinicopathological features and extremely poor prognosis.Frontiers in oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric carcinoma (GC) is a heterogeneous disease with diverse histopathological and molecular features. The Borrmann classification, which reflects the macroscopic growth pattern, has potential value in correlating with molecular characteristics and predicting disease extent and prognosis. However, its relationship with GC molecular subtypes remains incompletely defined. In the present study, we attempted to assess the relationship between Borrmann classification and clinical, pathological, and molecular findings in GC, as well as its impact on overall survival. MATERIAL AND
methodsA retrospective analysis was conducted on 255 patients who underwent surgery for GC between January 2012 and 2021. Cases were classified into types I, II, III, and IV, according to the Borrmann classification. Clinical data, tumor characteristics, molecular marker expression status, and survival data were analyzed in relation to the Borrmann classification.
resultThe most common macroscopic growth pattern was Borrmann type III (38.8%). Type IV tumors were associated with younger patients, larger size, epithelial-mesenchymal transition-related molecular subtype, diffuse histology, and a higher incidence of peritoneal dissemination. In contrast, type I tumors were more frequently diagnosed at earlier stages and demonstrated well-differentiated morphology, frequent HER2 positivity, and p53 mutant expression. Kaplan-Meier analysis demonstrated clear survival differences among Borrmann types, with type I tumors showing the most favorable outcomes (median 82.2 months) and type IV tumors the poorest (median 34.6 months; log-rank p < 0.001). When adjusted for covariates in the multivariate Cox model, only age, Borrmann type III (compared to type I) and advanced nodal status (pN0 compared to pN2-3) were found to be independent prognostic indicators. Advanced age was consistently associated with reduced survival time, type III tumors resulted in more than a twofold increase in mortality risk, and higher nodal stages were strongly linked to poor outcomes.
conclusionThe Borrmann classification showed associations with molecular and pathological features of GC, and survival varied among types, suggesting potential utility for prognostic assessment prior to surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.